BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2024. The put-call ratio across all filers is 0.01 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $39,693 | -26.8% | 117,260 | +22.1% | 0.00% | – |
| Q1 2024 | $54,245 | +106.9% | 96,060 | 0.0% | 0.00% | – |
| Q4 2023 | $26,224 | +36.4% | 96,060 | 0.0% | 0.00% | – |
| Q3 2023 | $19,222 | -90.3% | 96,060 | 0.0% | 0.00% | – |
| Q2 2023 | $197,884 | -37.6% | 96,060 | 0.0% | 0.00% | – |
| Q1 2023 | $316,998 | +0.6% | 96,060 | -50.0% | 0.00% | – |
| Q4 2022 | $315,076 | -25.9% | 192,120 | +100.0% | 0.00% | – |
| Q3 2022 | $425,000 | +60.4% | 96,060 | 0.0% | 0.00% | – |
| Q2 2022 | $265,000 | -18.0% | 96,060 | 0.0% | 0.00% | – |
| Q1 2022 | $323,000 | -6.9% | 96,060 | +10.8% | 0.00% | – |
| Q4 2021 | $347,000 | +21.3% | 86,703 | 0.0% | 0.00% | – |
| Q3 2021 | $286,000 | -13.1% | 86,703 | 0.0% | 0.00% | – |
| Q2 2021 | $329,000 | -83.4% | 86,703 | -83.2% | 0.00% | – |
| Q1 2021 | $1,982,000 | -7.7% | 517,363 | +9.0% | 0.00% | – |
| Q4 2020 | $2,148,000 | -72.7% | 474,691 | +2.0% | 0.00% | -100.0% |
| Q3 2020 | $7,876,000 | +66.2% | 465,492 | +10.1% | 0.00% | – |
| Q2 2020 | $4,738,000 | – | 422,678 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 400,000 | $1,068,000 | 0.09% |
| SABBY MANAGEMENT, LLC | 493,191 | $1,317,000 | 0.07% |
| GUARDIAN CAPITAL ADVISORS LP | 10,000 | $23,000 | 0.00% |
| A.R.T. Advisors, LLC | 22,758 | $60,000 | 0.00% |
| Psagot Value Holdings Ltd. | 22,715 | $61,000 | 0.00% |
| TCI Wealth Advisors, Inc. | 1,100 | $3,000 | 0.00% |
| Penserra Capital Management LLC | 4,980 | $13,000 | 0.00% |
| D'Orazio & Associates, Inc. | 500 | $1,000 | 0.00% |
| CITIGROUP INC | 380 | $1,000 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 61,269 | $163,000 | 0.00% |